



The Biomedical Advanced Research and Development Authority (BARDA), a component of HHS/ASPR, is responsible for the advanced development, manufacturing, testing, and acquisition of medical countermeasures including vaccines for chemical, biological, radiological, and nuclear threats, pandemic influenza, and emerging infectious diseases. For influenza, we have supported the development of seasonal and pandemic influenza vaccines manufactured using modern cell- and recombinant- based technologies and containing adjuvants that have been licensed by the FDA; established and maintained the national pre-pandemic influenza vaccine stockpile for H5N1, H7N9, and other viral antigens and oil-in-water emulsion adjuvants; expanded domestic influenza vaccine manufacturing capacity through public-private partnerships using our Centers for Innovation in Advanced Development and Manufacturing and Fill Finish Manufacturing Network; built manufacturing capacity in developing countries with WHO through expansion of facility infrastructure and technical expertise; and today with NIAID supporting the development of novel influenza vaccines that may be more effective and have universal potential. For smallpox, we supported the development and acquisition of a smallpox vaccine for immunocompromised persons that may be formulated as a longer-life lyophilized product. For anthrax, we supported the development of the FDA-licensed killed, whole organism vaccine; today the development of that vaccine with an adjuvant requiring fewer doses but delivering better immunity; and development of several rPA-based next generation anthrax vaccines. For Ebola, in partnership with NIAID, CDC, and DoD and industry, we have supported the development, manufacturing, and testing of multiple Ebola vaccine candidates using viral vectors for later consideration towards acquisition and stockpiling. For MERS-CoV, we are working with NIAID and the Saudi Arabian health authorities to establish a clinical study infrastructure to evaluate MERS-CoV vaccine and therapeutic candidates. As new infectious diseases emerge like Zika virus, we will engage our partners and activate our National MCM Response Infrastructure to help develop, manufacture, and test new vaccine candidates. Currently we are soliciting proposals for innovative vaccine platform technologies that may be used develop new vaccines and/or respond to emerging infectious diseases.